<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 29.6 - Vulvovaginal Candidiasis [SDL]</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 29.6 - Vulvovaginal Candidiasis [SDL] | MD3 SCP Cases">
  <meta name="description" content="Self-directed learning case on vulvovaginal candidiasis (thrush) covering clinical features, risk factors, treatment, and recurrent infection management.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://md3-scp.netlify.app/cases/case29_6.html">
  <meta property="og:title" content="Case 29.6 - Vulvovaginal Candidiasis [SDL]">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="Self-directed learning case on vulvovaginal candidiasis (thrush) covering clinical features, risk factors, treatment, and recurrent infection management.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <!-- Twitter -->
  <meta property="twitter:card" content="summary">
  <meta property="twitter:title" content="Case 29.6 - Vulvovaginal Candidiasis [SDL]">
  <meta property="twitter:description" content="Self-directed learning case on vulvovaginal candidiasis (thrush) covering clinical features, risk factors, treatment, and recurrent infection management.">
  <meta property="twitter:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">

  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 29.6 – Vulvovaginal Candidiasis [SDL]</h1>
    <p class="meta"><strong>Category:</strong> Medicine | <strong>Discipline:</strong> Sexual Health & Gynaecology | <strong>Setting:</strong> Self-Directed Learning</p>

    <h2>Learning Objectives</h2>
    <p>This is a <strong>self-directed learning (SDL)</strong> case. Use the key learning points below to guide your independent study of vulvovaginal candidiasis.</p>

    <h2>Key Topics to Cover</h2>
    <div class="key-points">
      <ul>
        <li><strong>Definition:</strong> Vulvovaginal candidiasis (VVC / "thrush") = fungal infection of vulva and vagina caused by <em>Candida</em> species - <strong>NOT a sexually transmitted infection</strong></li>
        <li><strong>Causative organism:</strong> <em>Candida albicans</em> (85-90%), <em>C. glabrata</em> (5-10% - more common in recurrent VVC, resistant to azoles)</li>
        <li><strong>Epidemiology:</strong> 75% of women experience at least one episode in their lifetime, 40-45% have ≥2 episodes</li>
        <li><strong>Pathophysiology:</strong> <em>Candida</em> is normal vaginal commensal - overgrowth occurs when protective lactobacilli depleted or local immunity impaired</li>
        <li><strong>Risk factors:</strong>
          <ul>
            <li><strong>Antibiotic use:</strong> Kills protective lactobacilli → allows <em>Candida</em> overgrowth (most common precipitant)</li>
            <li><strong>High oestrogen states:</strong> Pregnancy, COCP (high-dose), HRT - oestrogen promotes <em>Candida</em> growth</li>
            <li><strong>Immunosuppression:</strong> Diabetes (especially poorly controlled - high glucose), HIV, corticosteroids, chemotherapy</li>
            <li><strong>Other:</strong> Tight clothing, perfumed soaps/bubble baths, douching (disrupts vaginal flora)</li>
          </ul>
        </li>
        <li><strong>Clinical features:</strong>
          <ul>
            <li><strong>Vulval itching (pruritus) - KEY SYMPTOM</strong> - often intense</li>
            <li><strong>Vulval soreness, burning, irritation</strong></li>
            <li><strong>Vaginal discharge:</strong> Thick, white, "cottage cheese" appearance, <strong>non-offensive odor</strong> (unlike BV/TV)</li>
            <li><strong>Dyspareunia</strong> (superficial - due to vulval inflammation)</li>
            <li><strong>External dysuria</strong> (stinging on urination - urine on inflamed vulva)</li>
            <li><strong>Examination:</strong> Vulval erythema, edema, fissuring, satellite lesions, thick white adherent plaques on vaginal walls</li>
          </ul>
        </li>
        <li><strong>Diagnosis:</strong>
          <ul>
            <li><strong>Clinical diagnosis</strong> (typical symptoms + examination findings) - investigations not routinely required</li>
            <li><strong>High vaginal swab (HVS):</strong> If diagnosis uncertain, recurrent VVC, or treatment failure
              <ul>
                <li>Microscopy: Spores/pseudohyphae (KOH wet mount or Gram stain)</li>
                <li>Culture: Confirms <em>Candida</em> species (distinguish <em>C. albicans</em> vs <em>C. glabrata</em>)</li>
                <li><strong>Note:</strong> <em>Candida</em> can be normal commensal (30% of asymptomatic women) - positive swab without symptoms does NOT require treatment</li>
              </ul>
            </li>
            <li><strong>pH testing:</strong> Normal vaginal pH (3.5-4.5) - pH >4.5 suggests BV or TV (not VVC)</li>
          </ul>
        </li>
        <li><strong>Differential diagnosis:</strong>
          <ul>
            <li><strong>Bacterial vaginosis:</strong> Thin grey discharge, fishy odor, pH >4.5, <strong>NO itching</strong></li>
            <li><strong>Trichomoniasis:</strong> Frothy yellow-green discharge, offensive odor, pH >4.5, vulval itching, strawberry cervix</li>
            <li><strong>Atrophic vaginitis:</strong> Postmenopausal, vaginal dryness, dyspareunia, no discharge</li>
            <li><strong>Contact dermatitis:</strong> History of irritant (soap, perfume), eczema/psoriasis</li>
          </ul>
        </li>
        <li><strong>Management (BASHH 2019 Guidelines):</strong>
          <ul>
            <li><strong>Uncomplicated VVC (first-line options - equivalent efficacy):</strong>
              <ul>
                <li><strong>Intravaginal imidazole (clotrimazole):</strong> Clotrimazole 500mg pessary single dose (or 200mg for 3 nights) - topical, minimal systemic absorption</li>
                <li><strong>Oral fluconazole 150mg single dose:</strong> Convenient (single oral dose), systemic - <strong>contraindicated in pregnancy</strong></li>
                <li><strong>Topical imidazole cream (clotrimazole 2%):</strong> Applied to vulva BD for 7 days - for external symptoms</li>
                <li><strong>Combination:</strong> Pessary + topical cream (if severe vulval symptoms)</li>
              </ul>
            </li>
            <li><strong>Pregnancy:</strong> Intravaginal imidazole ONLY (longer course - 7 days) - <strong>avoid oral fluconazole (teratogenic)</strong></li>
            <li><strong>Partner notification/treatment:</strong> NOT required (<em>Candida</em> is not an STI)</li>
            <li><strong>Advise:</strong> Avoid irritants (perfumed products, douching), wear loose cotton underwear, avoid sex until symptoms resolve</li>
          </ul>
        </li>
        <li><strong>Recurrent vulvovaginal candidiasis (RVVC):</strong> ≥4 episodes per year (affects 5-8% of women)
          <ul>
            <li><strong>Investigations:</strong> HVS (confirm diagnosis, identify species), exclude diabetes (HbA1c/fasting glucose), consider HIV testing</li>
            <li><strong>Management (BASHH 2019):</strong>
              <ul>
                <li><strong>Induction:</strong> Fluconazole 150mg every 3 days (total 3 doses over 1 week)</li>
                <li><strong>Maintenance:</strong> Fluconazole 150mg once weekly for 6 months (prevents recurrence in 90%)</li>
                <li><strong>If <em>C. glabrata</em> (azole-resistant):</strong> Intravaginal nystatin 100,000 units for 14 nights, or boric acid pessaries</li>
              </ul>
            </li>
            <li><strong>Lifestyle:</strong> Optimize diabetes control, avoid unnecessary antibiotics, probiotics (limited evidence - may help)</li>
          </ul>
        </li>
        <li><strong>Key points:</strong>
          <ul>
            <li><strong>VVC is NOT an STI</strong> - partner treatment not required</li>
            <li><strong>Antibiotic use is the most common trigger</strong> (consider prophylactic antifungal if recurrent post-antibiotics)</li>
            <li><strong>Fluconazole contraindicated in pregnancy</strong> - use topical imidazole</li>
            <li><strong>Recurrent VVC requires investigation</strong> (exclude diabetes, HIV, <em>C. glabrata</em>) + long-term suppressive therapy</li>
            <li><strong>Positive swab without symptoms does NOT require treatment</strong> (<em>Candida</em> is normal commensal)</li>
          </ul>
        </li>
      </ul>
    </div>

    <h2>Recommended Resources</h2>
    <p>Refer to your lecture notes, textbooks (e.g., Oxford Handbook of Obstetrics & Gynaecology, BASHH guidelines 2019), and online resources (BASHH, RCOG, NHS) to explore these topics in detail.</p>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/dark-mode.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        }
      }
    }// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          }
        }, 100);
      }
    });
    }
  </script>

</body>
</html>
